Cargando…
Biomarkers in renal cell carcinoma: Are we there yet?
Management of kidney cancer has undergone a paradigm shift with the approval of new therapies over the last two decades. Although these drugs have improved clinical outcomes in patients with kidney cancer, there are still a large number of patients who do not show objective responses. A multitude of...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Second Military Medical University
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566366/ https://www.ncbi.nlm.nih.gov/pubmed/34765444 http://dx.doi.org/10.1016/j.ajur.2021.05.013 |